Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6896125 | 1.00 | KCNH2 (0.41) | KCNH2MEN1KMT2AMAPTKDM4E | |
| Oxalic Acid SCHEMBL5780721 | 0.99 | KCNH2 (0.42) | KCNH2MEN1KMT2AMAPTKDM4E | |
| SCHEMBL5780290 | 0.95 | KCNH2 (0.42) | KCNH2MAPTCXCR4 | |
| SCHEMBL5781590 | 0.94 | KCNH2 (0.43) | KCNH2MAPT | |
| Oxalic Acid SCHEMBL5778829 | 0.93 | MEN1 (0.46) | KCNH2MEN1KMT2AMAPTKDM4E | |
| Oxalic Acid SCHEMBL5782385 | 0.90 | KDM4E (0.44) | MEN1KMT2AKDM4EALDH1A1CXCR4 | |
| SCHEMBL5777663 | 0.87 | CXCR4 (0.43) | KCNH2MAPTCCR8CXCR4 | |
| Oxalic Acid SCHEMBL5779548 | 0.87 | MEN1 (0.41) | KCNH2MEN1KMT2AMAPTKDM4E | |
| Oxalic Acid SCHEMBL6892216 | 0.87 | MEN1 (0.40) | KCNH2MEN1KMT2AMAPTKDM4E | |
| Oxalic Acid SCHEMBL5779827 | 0.87 | KCNH2 (0.47) | KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | claimed |
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | KCNH2 6/4885MEN1 3216/4885KMT2A 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.